GlaxoSmithKline has decided not to proceed with the worldwide development of Simplirix, its experimental vaccine for the prevention of genital herpes in women.

The decision follows the results of a Phase III trial, which showed although the drug had an acceptable safety profile, it did not meet its primary endpoint of preventing the disease.

The trial began in 2003 and involved more than 8,000 18 to 30-year-old women, who were vaccinated at 50 sites in the US and Canada.

It was conducted in collaboration with US National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health.